 |
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
||
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||||||||||||||||||||
Catalog Number: 10-1097-xx
Description: AP-dC-CE Phosphoramidite
| 1-[5'-O-(4,4'-Dimethoxytrityl)-?-D-2'-deoxyribofuranosyl]-9- (2-trifluoroacetamidoethoxy)-1,3-diaza-2-oxophenoxazine, 3'-[(2-cyanoethyl)-(N,N-diisopropyl)]phosphoramidite | ||
| Formula: C49H54F3N6O10P | M.W.: 974.97 | F.W.: 438.33 |
Diluent: Anhydrous Acetonitrile |
| Coupling: No changes needed from standard method recommended by synthesizer manufacturer. |
| Deprotection: AMA (Ammonium hydroxide/40% Methylamine 1:1 v/v) for 10 minutes at 65 °C is recommended. Note to prevent any modification of dC by Methylamine, use Ac-dC (10-1015-xx) during synthesis. |
| Storage: Refrigerated storage, maximum of 2-8°C, dry |
| Stability in Solution: 24 hours |
| Please Note: This product is covered by patents or patents pending owned by Isis Pharmaceuticals, Inc. ("Isis"). Purchase of this product includes a limited license to use this product solely for internal research. This license specifically excludes (and you have no right to use this product for): (a) therapeutic or diagnostic applications (including products or services that incorporate this product), (b) any in vivo toxicity/safety study in support of an investigational new drug application (or foreign counterpart), (c) resale (including sale of any products or services that incorporate this product) or (d) gene functionalization activities (including products or services that incorporate data derived from gene functionalization activities) if such activities have commercial application, any and all of which require a separate license from Isis. Neither this product nor any product created through its use may be used in human clinical trials. |
| Please see Terms and Conditions of Use |
| Catalog Information | Material Safety Data Sheet |
EXTINCTION DATA
| Item | Nucleoside | λMax-1 | Emax-1 | λMax-2 | Emax-2 | E260 |
| (nm) | (ml/µmole) | nm | (ml/µmole) | (ml/µmole) | ||
| 10-1097 | 362nm | 10.5 | 10.9 |
Literature Highlights
| Glen Report 18.1: Fluorous Affinity Purification of Oligonucleotides |
| Glen Report 19.2: AP-dC is compatible with PCR and is Highly Fluorescent |
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link for more detailed usage information with the various synthesizers.
| ABI 392/394 | |||||||||
| Cat.No. | Pack Size | Grams/ Pack | 0.1M Dil. (mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
| Approximate Number of Additions | |||||||||
| 10-1097-02 | 0.25grams | .25grams | 2.56 | 72 | 43.2 | 27 | 19.64 | 14.4 | 3.6 |
| 10-1097-90 | 100µmoles | .097grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
| 10-1097-95 | 50µmoles | .049grams | .5 | 3.33 | 2 | 1.25 | .91 | .67 | .17 |
| Expedite | |||||||||
| Cat.No. | Pack Size | Grams/ Pack | Dilution (mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
| Approximate Number of Additions | |||||||||
| 10-1097-02 | 0.25grams | .25grams | 3.83 | .07 | 70.2 | 43.88 | 31.91 | 4.39 | |
| 10-1097-90 | 100µmoles | .097grams | 1.5 | .07 | 23.6 | 14.75 | 10.73 | 1.48 | |
| 10-1097-95 | 50µmoles | .049grams | .75 | .07 | 8.6 | 5.38 | 3.91 | .54 | |
| Beckman | |||||||||
| Cat.No. | Pack Size | Grams/ Pack | Dilution (mL) | Molarity | 30nm | 200nm | 1000nm | ||
| Approximate Number of Additions | |||||||||
| 10-1097-02 | 0.25grams | .25grams | 3.83 | .07 | 71.8 | 44.88 | 32.64 | ||
| 10-1097-90 | 100µmoles | .097grams | 1.5 | .07 | 25.2 | 15.75 | 11.45 | ||
| 10-1097-95 | 50µmoles | .049grams | .75 | .07 | 10.2 | 6.38 | 4.64 | ||
08/15/2012 | http://www.glenres.com/ProductFiles/10-1097.html